Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immunome, Inc. IMNM
$6.68
+$0.33 (5.01%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
75478812.00000000
-
week52high
6.25
-
week52low
2.09
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.74263900
-
EPS
-3.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 29 окт 2021 г. | |
| Chardan Capital | Buy | 27 окт 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RAPP MICHAEL | A | 817366 | 17500 | 15 янв 2023 г. |
| Lefenfeld Michael | A | 40747 | 13875 | 15 янв 2023 г. |
| LAMATTINA JOHN L | A | 66953 | 15125 | 15 янв 2023 г. |
| WAGENHEIM PHILIP | A | 406147 | 8750 | 15 янв 2023 г. |
| Sarma Purnanand D | A | 121000 | 121000 | 16 июн 2022 г. |
| Stoneman Sandra G. | A | 43000 | 43000 | 16 июн 2022 г. |
| Giesing Dennis H | A | 60000 | 60000 | 16 июн 2022 г. |
| ROBINSON MATTHEW K | A | 35000 | 35000 | 16 июн 2022 г. |
| Roche Corleen M. | A | 70000 | 70000 | 16 июн 2022 г. |
| RAPP MICHAEL | A | 6500 | 6500 | 16 июн 2022 г. |
Новостная лента
Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration
Seeking Alpha
31 янв 2023 г. в 02:48
Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development. Even if IMNM can't find a partner for IMM-BCP-01, a new collaboration agreement with ABBV is arguably a more exciting development.
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
Investors Business Daily
06 янв 2023 г. в 13:45
AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal appeared first on Investor's Business Daily.
AbbVie and Immunome Partner to Find New Cancer Treatments
The Dog of Wall Street
06 янв 2023 г. в 11:17
Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.
Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data
Benzinga
19 мая 2022 г. в 15:44
Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus.
Why Immunome Shares Are Rising
Benzinga
19 мая 2022 г. в 14:24
Immunome Inc (NASDAQ: IMNM) shares are trading higher by 19.44% at $3.39 after the company published data demonstrating its COVID-19 antibody cocktail IMM-BCP-01 cleared the omicron variant of SARS-CoV-2 when tested in vivo in hamsters. When tested in hamster models, Immunome says IMM-BCP-01.